Amphastar Pharmaceuticals Property, Plant, and Equipment 2012-2024 | AMPH
Amphastar Pharmaceuticals property, plant, and equipment from 2012 to 2024. Property, plant, and equipment can be defined as the sum of all net property, plant & Equipment fields. Where companies do not report a break down of plant, property, & equipment, the value is entered in this field alone.
Amphastar Pharmaceuticals Annual Property, Plant, and Equipment
(Millions of US $) |
| 2023 |
$283 |
| 2022 |
$238 |
| 2021 |
$244 |
| 2020 |
$260 |
| 2019 |
$234 |
| 2018 |
$210 |
| 2017 |
$181 |
| 2016 |
$153 |
| 2015 |
$142 |
| 2014 |
$138 |
| 2013 |
$117 |
| 2012 |
$107 |
| 2011 |
$ |
| 2009 |
$0 |
Amphastar Pharmaceuticals Quarterly Property, Plant, and Equipment
(Millions of US $) |
| 2024-09-30 |
$295 |
| 2024-06-30 |
$288 |
| 2024-03-31 |
$289 |
| 2023-12-31 |
$283 |
| 2023-09-30 |
$281 |
| 2023-06-30 |
$279 |
| 2023-03-31 |
$243 |
| 2022-12-31 |
$238 |
| 2022-09-30 |
$233 |
| 2022-06-30 |
$238 |
| 2022-03-31 |
$243 |
| 2021-12-31 |
$244 |
| 2021-09-30 |
$243 |
| 2021-06-30 |
$253 |
| 2021-03-31 |
$253 |
| 2020-12-31 |
$260 |
| 2020-09-30 |
$246 |
| 2020-06-30 |
$238 |
| 2020-03-31 |
$231 |
| 2019-12-31 |
$234 |
| 2019-09-30 |
$222 |
| 2019-06-30 |
$220 |
| 2019-03-31 |
$215 |
| 2018-12-31 |
$210 |
| 2018-09-30 |
$203 |
| 2018-06-30 |
$198 |
| 2018-03-31 |
$192 |
| 2017-12-31 |
$181 |
| 2017-09-30 |
$173 |
| 2017-06-30 |
$162 |
| 2017-03-31 |
$157 |
| 2016-12-31 |
$153 |
| 2016-09-30 |
$152 |
| 2016-06-30 |
$149 |
| 2016-03-31 |
$145 |
| 2015-12-31 |
$142 |
| 2015-09-30 |
$141 |
| 2015-06-30 |
$139 |
| 2015-03-31 |
$138 |
| 2014-12-31 |
$138 |
| 2014-09-30 |
$134 |
| 2014-06-30 |
$134 |
| 2014-03-31 |
$119 |
| 2013-12-31 |
$117 |
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
$187 |
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.294B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
